Abstract: A novel compound to induce a pluripotent stem cell is provided. A novel anti-malignant-tumor substance is provided. A pluripotent stem cell-inducing agent, including one or more single-stranded or double-stranded polynucleotides selected from the group consisting of: a) a single-stranded or double-stranded polynucleotide containing a sequence of SEQ ID NO:1 or a sequence including deletion, substitution, or addition of 1 to 3 bases in SEQ ID No: 1, b) a single-stranded or double-stranded polynucleotide containing a sequence of SEQ ID NO:2 or a sequence including deletion, substitution, or addition of 1 to 3 bases in SEQ ID No: 2, c) a single-stranded or double-stranded polynucleotide containing a sequence of SEQ ID NO:3 or a sequence including deletion, substitution, or addition of 1 to 3 bases in SEQ ID No: 3, in which the pluripotent stem cell-inducing agent induces a cell to become a pluripotent stem cell is provided.

Abstract: This invention provides a vaccinia virus that grows specifically in a cancer cell and damages such cancer cell and the use of such virus for treatment of cancer. Such mitogen-activated protein kinase-dependent vaccinia virus strain lacks functions of vaccinia virus growth factor (VGF) and O1L, it does not grow in normal cells but grows specifically in cancer cells, and it has oncolytic properties that specifically damage cancer cells.

Abstract: A chimeric non-human animal having an in vivo human hepatocyte population, wherein the effects of non-human animal cells on drug metabolism are suppressed or deleted is provided. A method for producing a chimeric non-human animal that lacks a drug-metabolizing system or has a suppressed drug-metabolizing system and is provided with a drug-metabolizing system driven by human hepatocytes, is provided. The method comprises transplanting human hepatocytes into a non-human animal characterized by (i) being immunodeficient, (ii) having liver damage, and (iii) lacking the functions of an endogenous Cyp3a gene.

Abstract: A liquid crystal display panel includes: a liquid crystal layer including a liquid crystal material with positive dielectric constant anisotropy; a vertical alignment film being in contact with the liquid crystal layer; a first substrate and a second substrate disposed to face each other with the liquid crystal layer in between; and an electrode disposed on a surface of one or both of the first substrate and the second substrate and generating, in the liquid crystal layer, an electric field in a direction orthogonal to or intersecting with a normal to the first substrate.

Abstract: It is an object of the present invention to evaluate the induction of a drug-metabolizing enzyme by a test substance more accurately than ever before, by simple operations, using a vector in which a reporter gene is connected downstream of the expression control region of a drug-metabolizing enzyme gene and a cell into which the aforementioned vector is introduced. The present invention provides a vector for producing a cell that is used for evaluation of the induction of a drug-metabolizing enzyme by a test substance and the cytotoxicity of the test substance, the vector comprising an expression control region of a fetus-specific gene, a first reporter gene, an expression control region of a drug-metabolizing enzyme gene, and a second reporter gene, wherein the first reporter gene is located downstream of the expression control region of the fetus-specific gene and the second reporter gene is located downstream of the expression control region of the drug-metabolizing enzyme gene.

Abstract: A manufacturing apparatus and a manufacturing method of pet food are provided. The manufacturing apparatus comprises a material inlet through which a kneaded material is fed, the kneaded material being obtained through kneading a raw pet food material; an extrusion molding section configured to extrude the kneaded material through an extruding outlet; a cutter configured to cut the kneaded material extruded through the extruding outlet at desired intervals to form material grains; a reservoir disposed in a location to receive the material grains falling due to the cutting; an agitating section provided in the reservoir and configured to agitate the material grains; a heating section configured to heat the material grains while the material grains are agitated by the agitating section; and a drying section configured to dry the material grains within the reservoir after the heating.

Abstract: Disclosed is a mouse artificial chromosome vector, comprising: a natural centromere derived from a mouse chromosome; a mouse-chromosome-derived long-arm fragment formed by deleting a long-arm distal region at a mouse chromosome long-arm site proximal to the centromere; and a telomere sequence, wherein the vector is stably retained in a cell and/or tissue of a mammal. In addition, disclosed are cells or non-human animals comprising the vector, and use of the cells or non-human animals.

Abstract: The present invention provides a side effect inhibitor of drug therapy for colorectal cancer using 5-fluorouracil, comprising fucoidan or a fucoidan-containing material; a method for inhibiting side effects of drug therapy for colorectal cancer using 5-fluorouracil, which comprises administering fucoidan or a fucoidan-containing material to a colorectal cancer patient; and use of fucoidan or a fucoidan-containing material for the production of a side effect inhibitor of drug therapy for colorectal cancer using 5-fluorouracil.

Abstract: This invention relates to a mammalian artificial chromosome vector, which retains a human chromosome 7 fragment comprising human cytochrome P450 genes and is transmittable to progeny, wherein the human chromosome 7 fragment retains a region of approximately 1 Mb±500 Kb in size comprising at least a human CYP3A gene cluster, which region is located between chromosome markers AC004922 and AC073842, and to a non-human mammalian animal retaining the vector.

Abstract: Disclosed is a mouse artificial chromosome vector, comprising: a natural centromere derived from a mouse chromosome; a mouse-chromosome-derived long-arm fragment formed by deleting a long-arm distal region at a mouse chromosome long-arm site proximal to the centromere; and a telomere sequence, wherein the vector is stably retained in a cell and/or tissue of a mammal. In addition, disclosed are cells or non-human animals comprising the vector, and use of the cells or non-human animals.

Abstract: The purpose of the present invention is to provide a novel therapeutic agent or a novel prophylactic agent for diseases associated with abnormal glucose metabolism. The present invention is a therapeutic agent or a prophylactic agent for diseases associated with abnormal glucose metabolism, which comprises a 2-phenylthiazole compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: The present invention provides a therapeutic and/or prophylactic agent for inflammatory bowel disease and an NF-kB activation inhibitor, each of which comprises chitin nanofibers or chitosan nanofibers.

Abstract: There are provided a pressure sensor which can avoid an endoscope from causing intestinal perforation, an endoscope including the pressure sensor, and an endoscope device including the endoscope. There is provided a pressure sensor including a support unit and a pressure sensitive unit disposed on the ridge line of the front end of the support unit and configured to output a signal corresponding to an applied pressure. The pressure sensitive unit includes a first electrode disposed in a ring shape and multiple second electrodes opposed to the first electrode. The second electrodes are spaced in the circumferential direction of the first electrode.

Abstract: A chimeric non-human animal having an in vivo human hepatocyte population, wherein the effects of non-human animal cells on drug metabolism are suppressed or deleted is provided. A method for producing a chimeric non-human animal that lacks a drug-metabolizing system or has a suppressed drug-metabolizing system and is provided with a drug-metabolizing system driven by human hepatocytes, is provided. The method comprises transplanting human hepatocytes into a non-human animal characterized by (i) being immunodeficient, (ii) having liver damage, and (iii) lacking the functions of an endogenous Cyp3a gene.

Abstract: There is provided a substance having much higher catalytic activity for a Suzuki-Miyaura coupling reaction than conventional heterogenous catalysts. The present invention provides a zeolite-palladium complex including USY-zeolite and Pd supported on the USY-zeolite, the Pd having a Pd—Pd coordination number of 4 or less and an oxidation number of 0.5 or less.

Abstract: A diagnosis processing device is provided in which diagnosis is realizable by a simple arrangement. A diagnosis processing device (1) of the present invention includes: a learning pattern creating section (10a) for creating a learning pattern by sampling data from a learning image in which abnormality information indicating a substantive feature of abnormality of a target is pre-known; a learning processing section (12) for causing a neural network (17) to learn, by using learning patterns; a diagnostic pattern creating section (10b) for creating a diagnostic pattern by sampling data from a diagnostic image in which abnormality information is unknown; a determination processing section (18) for determining a substantive feature of the abnormality of the target indicated in the abnormality information in the diagnostic image, based on an output value outputted, in response to an input of the diagnostic pattern, from a learned neural network (17) which is a neural network subjected to learning.

Abstract: The purpose is to select low-molecular-weight compounds which are effective in inducing differentiation of mesenchymal stem cell into hepatocyte and to develop a safe differentiation-inducing method having excellent efficiency of differentiating mesenchymal stem cell into hepatocyte. Provided are at least one compound selected from the group consisting of compounds represented by formulae (1) and (2), a salt thereof, or a solvate of them; a differentiation inducer comprising at least one compound selected from the group consisting of compounds represented by formulae (1) and (2), a salt thereof, or a solvate of them; and a differentiation inducer comprising a compound represented by formula (8), a salt thereof, or a solvate of them.

Abstract: A solvent composition includes a substance that is subject to oxidative alteration by an oxygen radical, and a compound that has a superoxide dismutase-mimetic activity that includes oxygen radical-removing capability. In the solvent composition of the invention, oxygen radicals can be removed by the compound having an superoxide dismutase-mimetic activity that includes oxygen radical-removing capability, and therefore the substance that is subject to oxidative alteration can be prevented from oxidizing.

Abstract: A novel compound to induce a pluripotent stem cell is provided. A novel anti-malignant-tumor substance is provided. A pluripotent stem cell-inducing agent, including a single-stranded or double-stranded polynucleotide containing the base sequence shown in SEQ ID NO:41 or a base sequence including deletion, substitution, or addition of 1 to 3 bases in SEQ ID No: 41, in which the pluripotent stem cell-inducing agent induces a cell to become a pluripotent stem cell is provided.

Abstract: A novel compound to induce a pluripotent stem cell is provided. A novel anti-malignant-tumor substance is provided. A pluripotent stem cell-inducing agent, including one or more single-stranded or double-stranded polynucleotides selected from the group consisting of: a) a single-stranded or double-stranded polynucleotide containing a sequence of SEQ ID NO:1 or a sequence including deletion, substitution, or addition of 1 to 3 bases in SEQ ID No: 1, b) a single-stranded or double-stranded polynucleotide containing a sequence of SEQ ID NO:2 or a sequence including deletion, substitution, or addition of 1 to 3 bases in SEQ ID No: 2, c) a single-stranded or double-stranded polynucleotide containing a sequence of SEQ ID NO:3 or a sequence including deletion, substitution, or addition of 1 to 3 bases in SEQ ID No: 3, in which the pluripotent stem cell-inducing agent induces a cell to become a pluripotent stem cell is provided.